Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases

References

• Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516–524. doi:10.1038/nrclinonc.2016.30
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535
   PubMed Web of Science ®Google Scholar
• Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for oligometastatic lung cancer. Front Oncol. 2017;7:210. doi:10.3389/fonc.2017.00210
   PubMed Web of Science ®Google Scholar
• Vrankar M. Challenges in the treatment of oligometastatic non-small cell lung cancer. In: Lung Cancer-Modern Multidisciplinary Management. IntechOpen; 2020.
   Google Scholar
• Rheinheimer S, Heussel CP, Mayer P, et al. Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors. Cancers. 2020;12(4):Apr. doi:10.3390/cancers12041046
   Web of Science ®Google Scholar
• Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–4101. doi:10.1118/1.3438081
   PubMed Web of Science ®Google Scholar
• Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109(1):1–7. doi:10.1016/j.radonc.2013.09.006
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial. JAMA Oncology. 2018;4(9):1263–1266. doi:10.1001/jamaoncol.2018.1251
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial. J Clin Oncol. 2020;38(25):2830–2838. doi:10.1200/jco.20.00818
   PubMed Web of Science ®Google Scholar
• Maehata Y, Onishi H, Kuriyama K, et al. Immune responses following stereotactic body radiotherapy for stage I primary lung cancer. Biomed Res Int. 2013;2013:1–11. doi:10.1155/2013/731346
   Web of Science ®Google Scholar
• Lee DH, Kim SK, Lee HY, et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol. 2009;4(7):816–821. doi:10.1097/JTO.0b013e3181a99fde
   PubMed Web of Science ®Google Scholar
• Gehan EA, Tefft MC. Will there be resistance to the RECIST (response evaluation criteria in solid tumors)? J Natl Cancer Inst. 2000;92(3):179–181. doi:10.1093/jnci/92.3.179
   PubMedGoogle Scholar
• Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669–3676. doi:10.1007/s00520-016-3297-9
   PubMed Web of Science ®Google Scholar
• Win T, Miles KA, Janes SM, et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(13):3591–3599. doi:10.1158/1078-0432.Ccr-12-1307
   PubMed Web of Science ®Google Scholar
• Bankier AA, MacMahon H, Goo JM, Rubin GD, Schaefer-Prokop CM, Naidich DP. Recommendations for measuring pulmonary nodules at CT: a statement from the fleischner society. Radiology. 2017;285(2):584–600. doi:10.1148/radiol.2017162894
   PubMed Web of Science ®Google Scholar
• Li M, Yang X, Chen Y, et al. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:2885–2892. doi:10.2147/ott.S138701
   PubMed Web of Science ®Google Scholar
• Corrales L, Nogueira A, Passiglia F, et al. Second-line treatment of non-small cell lung cancer: clinical, pathological, and molecular aspects of nintedanib. Front Med. 2017;4:13. doi:10.3389/fmed.2017.00013
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076. doi:10.1001/jama.2010.261
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non–small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–682. doi:10.1016/j.ijrobp.2008.11.042
   PubMed Web of Science ®Google Scholar
• Murray P, Franks K, Hanna GG. A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer. Br J Radiol. 2017;90(1071):20160732. doi:10.1259/bjr.20160732
   PubMed Web of Science ®Google Scholar
• Sharma A, Baker S, Duijm M, et al. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy. Radiother Oncol. 2020;144:23–29. doi:10.1016/j.radonc.2019.10.004
   PubMed Web of Science ®Google Scholar
• Pasalic D, Lu Y, Betancourt-Cuellar SL, et al. Stereotactic ablative radiation therapy for pulmonary metastases: improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol. 2020;145:178–185. doi:10.1016/j.radonc.2020.01.010
   PubMed Web of Science ®Google Scholar
• Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010;5(7):1091–1099. doi:10.1097/JTO.0b013e3181de7143
   PubMed Web of Science ®Google Scholar
• Macbeth F. Avoid futile therapy. Int J Radiat Oncol Biol Phys. 2017;99(4):768. doi:10.1016/j.ijrobp.2017.02.035
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Yang J, Guttmann D, et al. Consolidative use of radiotherapy to block (CURB) oligoprogression―interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. Int J Radiat Oncol Biol Phys. 2021;111(5):1325–1326. doi:10.1016/j.ijrobp.2021.09.014
   Web of Science ®Google Scholar
• Allibhai Z, Taremi M, Bezjak A, et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;87(5):1064–1070. doi:10.1016/j.ijrobp.2013.08.020
   PubMed Web of Science ®Google Scholar
• Sheikhbahaei S, Mena E, Marcus C, Wray R, Taghipour M, Subramaniam RM. 18F-FDG PET/CT: therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients. J Nucl Med. 2016;57(6):855–860. doi:10.2967/jnumed.115.165480
   PubMed Web of Science ®Google Scholar
• Tumati V, Iyengar P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 21):S2537. doi:10.21037/jtd.2018.07.19
   PubMed Web of Science ®Google Scholar
• Formenti SC. Optimizing dose per fraction: a new chapter in the story of the abscopal effect? Int J Radiat Oncol Biol Phys. 2017;99(3):677–679. doi:10.1016/j.ijrobp.2017.07.028
   PubMed Web of Science ®Google Scholar
• Gomez DR, Blumenschein JGR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682. doi:10.1016/S1470-2045(16)30532-0
   PubMed Web of Science ®Google Scholar
• Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non–small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncology. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.3501
   PubMed Web of Science ®Google Scholar
• Palma DA, Salama JK, Lo SS, et al. The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549–557. doi:10.1038/nrclinonc.2014.96
   PubMed Web of Science ®Google Scholar
• Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84. doi:10.1016/j.lungcan.2014.07.020
   PubMed Web of Science ®Google Scholar